文献速递乳腺技术与安全US

自动与手持乳腺超声补充筛查结果比较

Comparison of Supplemental Breast Cancer Screening Outcomes for Automated Versus Handheld Ultrasound.
PubMed 文献 · J Am Coll Radiol · 2026-07-30

该研究基于美国乳腺监测联盟三个登记处27家机构2017-2020年间21110例HHUS和4218例ABUS检查数据,比较致密乳腺女性补充超声筛查效果。结果显示ABUS异常判读率、短期随访推荐率及假阳性初始评估率均低于HHUS,两者癌症检出率相似。

要点

  • ABUS异常判读率及短期随访推荐率低于HHUS,可减少不必要的短期随访。
  • ABUS与HHUS癌症检出率相似,可考虑作为致密乳腺女性补充筛查替代手段。
  • ABUS假阳性初始评估率低于HHUS,有助于降低筛查相关焦虑与额外检查。

核心结论

  • ABUS较HHUS异常判读率、短期随访推荐率及假阳性初始评估率更低,活检推荐率、假阳性活检推荐率、阳性预测值及癌症检出率未见明显差异。

研究设计与样本

  • 观察性研究,利用乳腺监测联盟三个登记处27家放射科机构2017-2020年的数据。
  • 纳入21110例HHUS检查和4218例ABUS检查,对象为致密乳腺女性。

诊断标准与关键数值

  • ABUS与HHUS在活检推荐率、假阳性活检推荐率、阳性预测值及癌症检出率上无明显差异。

临床应用与阅片要点

  • 对于致密乳腺女性,ABUS可作为HHUS的有效替代进行补充筛查。
  • ABUS较低的异常判读率和短期随访推荐率有助于减少患者短期复查负担。

局限性

  • 该研究为观察性设计,检查方式选择可能存在适应证偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Supplemental ultrasound as an adjuvant to screening mammography has expanded due in part to the implementation of state laws mandating breast density notification. Automated breast ultrasound (ABUS) is an emerging modality that can potentially improve reproducibility and reduce operator dependency associated with handheld ultrasound (HHUS) in appropriately selected patients. The goals of these analyses were to compare the performance of ABUS versus HHUS for women with dense breasts.

METHODS: We used observational data from 21,110 HHUS and 4,218 ABUS examinations among women with dense breasts conducted during 2017-2020 at 27 radiology facilities within three Breast Cancer Surveillance Consortium registries. Differences in abnormal interpretation rate, short-interval follow-up recommendation rate, biopsy recommendation rate, and cancer detection rate, as well as the false-positive initial assessment rate, false-positive biopsy recommendation rate, and positive predictive values for initial assessment and biopsy recommendation were compared.

RESULTS: ABUS was associated with a lower abnormal interpretation rate (14.9% versus 19.2%, P < .0001), a lower short-interval follow-up recommendation rate (3.0% versus 14.6%, P < .0001), and a lower false-positive initial assessment rate (14.6 versus 19.1; P < .0001) compared with HHUS. There were no apparent differences in biopsy recommendation or false-positive biopsy recommendation rate, positive predictive value, or cancer detection rate for ABUS versus HHUS.

CONCLUSION: Compared with HHUS, ABUS was associated with fewer abnormal interpretations and fewer short-interval follow-up recommendations and with a similar cancer detection rate. ABUS should be considered by health care providers as an effective alternative to handheld ultrasound for screening of certain women with dense breasts.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Rauscher, Alsheik, Eavey, et al. Comparison of Supplemental Breast Cancer Screening Outcomes for Automated Versus Handheld Ultrasound. J Am Coll Radiol. 2026. PMID: 42398688. doi:10.1016/j.jacr.2026.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。